NZ531527A - A composition consisting aqueous free nucleic acid and anti-inflammatory/immuno-suppressive agent for achieving persistent transgene expression - Google Patents

A composition consisting aqueous free nucleic acid and anti-inflammatory/immuno-suppressive agent for achieving persistent transgene expression

Info

Publication number
NZ531527A
NZ531527A NZ531527A NZ53152700A NZ531527A NZ 531527 A NZ531527 A NZ 531527A NZ 531527 A NZ531527 A NZ 531527A NZ 53152700 A NZ53152700 A NZ 53152700A NZ 531527 A NZ531527 A NZ 531527A
Authority
NZ
New Zealand
Prior art keywords
composition
inflammatory
composition according
nucleic acid
expression
Prior art date
Application number
NZ531527A
Other languages
English (en)
Inventor
Patrick Lu
David Leonard Ennist
Mervat Mina
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ531527A publication Critical patent/NZ531527A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ531527A 1999-12-28 2000-12-27 A composition consisting aqueous free nucleic acid and anti-inflammatory/immuno-suppressive agent for achieving persistent transgene expression NZ531527A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47301899A 1999-12-28 1999-12-28

Publications (1)

Publication Number Publication Date
NZ531527A true NZ531527A (en) 2005-10-28

Family

ID=23877847

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ531527A NZ531527A (en) 1999-12-28 2000-12-27 A composition consisting aqueous free nucleic acid and anti-inflammatory/immuno-suppressive agent for achieving persistent transgene expression

Country Status (8)

Country Link
EP (1) EP1242608A2 (de)
JP (1) JP2003522133A (de)
CN (2) CN1310679C (de)
AU (1) AU3164801A (de)
CA (1) CA2395544A1 (de)
IL (1) IL150485A0 (de)
NZ (1) NZ531527A (de)
WO (1) WO2001048231A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223718B2 (en) * 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
CN101495498B (zh) * 2005-02-07 2013-09-18 基因信息公司 轻度骨关节炎生物标志物及其用途
US20070225233A1 (en) * 2006-03-27 2007-09-27 Tsu-Fuh Yeh Reducing the risk of chronic lung disease in infants
CN113384705A (zh) * 2021-06-28 2021-09-14 西南大学 泊洛沙姆修饰的脂质体的制备及在口服药物递送中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0465529B1 (de) * 1989-03-21 1998-04-29 Vical, Inc. Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
EP1181937A3 (de) * 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
EP0804076A4 (de) * 1994-10-19 1998-10-21 Genetic Therapy Inc Gentherapy durch gleichzeitige und wiederholte verabreichung von adenovirus und immunsuppresiven mitteln
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6353055B1 (en) * 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
WO1996015780A1 (en) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection
MY134778A (en) * 1995-10-23 2007-12-31 Hyal Pharmaceutical Australia Ltd Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
ATE321882T1 (de) * 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre

Also Published As

Publication number Publication date
CA2395544A1 (en) 2001-07-05
CN101011584A (zh) 2007-08-08
CN1310679C (zh) 2007-04-18
EP1242608A2 (de) 2002-09-25
CN1433477A (zh) 2003-07-30
AU3164801A (en) 2001-07-09
WO2001048231A2 (en) 2001-07-05
IL150485A0 (en) 2002-12-01
JP2003522133A (ja) 2003-07-22
WO2001048231A3 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
Brigham et al. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy
US20210379203A1 (en) New Tools for Improving Gene Therapy and Use Thereof
Gautam et al. Delivery systems for pulmonary gene therapy
AU732447B2 (en) Gene delivery and expression in areas inaccessible to direct protein delivery
NZ531527A (en) A composition consisting aqueous free nucleic acid and anti-inflammatory/immuno-suppressive agent for achieving persistent transgene expression
JP7236446B2 (ja) コア－シェル構造のマイクロ粒子を有効成分として含む血液凝固因子遺伝子発現増加用組成物
EP1898945B1 (de) Atemwegs-administration eines standort-deaktivierten fviia bei entzündungskrankheiten, die den atemtrakt betreffen
US20030148975A1 (en) Method of achieving persistent transgene expression
US7074399B2 (en) Treatment of inflammation with p20
JP2001270840A (ja) 免疫疾患の治療
AU2004240187A1 (en) Method of achieving persistent transgene expression
JP2003500419A (ja) 肺疾患の遺伝子治療
US20060246074A1 (en) Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, in combination with alpha 1- antitrypsin polypeptides, or nucleic acids encoding them, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds
US20040171122A1 (en) Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same
FLOTTE SECTION I GENETIC AND DEVELOPMENTAL BIOLOGY OF THE RESPIRATORY SYSTEM
Brigham et al. Rationale for the use of Gene Therapy for Critical Illness
NZ616479B2 (en) Complement factor b analogs and their uses
MX2007016372A (es) Administracion a las vias respiratorias de la proteina c activada en condiciones inflamatorias que afectan el tracto respiratorio

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)